

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

JASVINDER A. SINGH,¹ KENNETH G. SAAG,¹ S. LOUIS BRIDGES JR.,¹ ELIE A. AKL,² RAVEENDHARA R. BANNURU,³ MATTHEW C. SULLIVAN,³ ELIZAVETA VAYSBROT,³ CHRISTINE MCNAUGHTON,³ MIKALA OSANI,³ ROBERT H. SHMERLING,⁴ JEFFREY R. CURTIS,¹ DANIEL E. FURST,⁵ DEBORAH PARKS,⁶ ARTHUR KAVANAUGH,⁷ JAMES O'DELL,⁸ CHARLES KING,⁹ AMYE LEONG,¹⁰ ERIC L. MATTESON,¹¹ JOHN T. SCHOUSBOE,¹² BARBARA DREVLLOW,¹³ SETH GINSBERG,¹⁴ JAMES GROBER,¹³ E. WILLIAM ST. CLAIR,¹⁵ ELIZABETH TINDALL,¹⁶ AMY S. MILLER,¹⁷ AND TIMOTHY MCALINDON³

Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to the recommendations within this guideline to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed and endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice. ACR recommendations are not intended to dictate payment or insurance decisions. These recommendations cannot adequately convey all uncertainties and nuances of patient care.

The ACR is an independent, professional, medical and scientific society that does not guarantee, warrant, or endorse any commercial product or service.

This article is published simultaneously in *Arthritis & Rheumatology*.

The views expressed herein are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

Supported by the American College of Rheumatology.

¹Jasvinder A. Singh, MBBS, MPH, Kenneth G. Saag, MD, MSc, S. Louis Bridges Jr., MD, PhD, Jeffrey R. Curtis, MD, MS, MPH: University of Alabama at Birmingham; ²Elie A. Akl, MD, MPH, PhD: American University of Beirut, Beirut, Lebanon, and McMaster University, Hamilton, Ontario, Canada; ³Raveendhara R. Bannuru, MD, PhD, Matthew C. Sullivan, BA, Elizaveta Vaysbrot, MD, MS, Christine McNaughton, BS, Mikala Osani, BA, Timothy McAlindon, MD, MPH: Tufts Medical Center, Boston, Massachusetts; ⁴Robert H. Shmerling, MD: Beth Israel Deaconess Medical Center, Boston, Massachusetts; ⁵Daniel E. Furst, MD, MS: University of California, Los Angeles; ⁶Deborah Parks, MD: Washington University School of Medicine, St. Louis, Missouri; ⁷Arthur Kavanaugh, MD: University of California, San Diego; ⁸James O'Dell, MD: University of Nebraska Medical Center, Omaha; ⁹Charles

King, MD: North Mississippi Medical Center, Tupelo; ¹⁰Amye Leong, MBA: Healthy Motivation, Santa Barbara, California; ¹¹Eric L. Matteson, MD, MPH: Mayo Clinic, Rochester, Minnesota; ¹²John T. Schousboe, MD, PhD: University of Minnesota and Park Nicollet Clinic, St. Louis Park; ¹³Barbara Drevlow, MD, James Grober, MD: NorthShore University Health System, Evanston, Illinois; ¹⁴Seth Ginsberg, BSc: Global Healthy Living Foundation, New York, New York; ¹⁵E. William St. Clair, MD: Duke University Medical Center, Durham, North Carolina; ¹⁶Elizabeth Tindall, MD: Rheumatology Consultants of Oregon, West Linn; ¹⁷Amy S. Miller: American College of Rheumatology, Atlanta, Georgia.

Dr. Singh has received consulting fees, speaking fees, and/or honoraria from Savient, Allergan, Regeneron, Merz, Iroko, and Bioiberica (less than \$10,000 each) and from Takeda and Dinora (more than \$10,000 each), and has received grant/research support from Horizon. Dr. Saag has received consulting fees, speaking fees, and/or honoraria from Abbott, Amgen, Bayer, Bristol-Myers Squibb, Lilly, Merck, Pfizer, and Roche/Genentech (less than \$10,000 each) and from Ardea/AstraZeneca (more than \$10,000). Dr. Curtis has received con-

Objective. To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA).

Methods. We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences.

Results. The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥ 6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional.

Conclusion. This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

INTRODUCTION

Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults (1). RA has a sig-

nificant negative impact on the ability to perform daily activities, including work and household tasks, and health-related quality of life, and it increases mortality (2–4). The American College of Rheumatology (ACR) last published a guideline for RA management in 2012 (5), which was an update of the 2008 RA guideline (6).

Because there has been rapid accrual of evidence and new therapies, advancement of guideline development methodologies, and the need to broaden the scope of its 2012 RA pharmacologic treatment guideline. This guideline addresses 6 major topics: 1) use of traditional disease-modifying antirheumatic drugs (traditional/conventional DMARDs, herein referred to as DMARDs), biologic DMARDs (herein referred to as biologics), and tofacitinib, including tapering and discontinuing medications, and a treat-to-target approach; 2) use of glucocorticoids; 3) use of biologics and DMARDs in high-risk populations (i.e., those with hepatitis, congestive heart failure, malignancy, and serious infections); 4) use of vaccines in patients starting/receiving DMARDs or biologics; 5) screening for tuberculosis (TB) in the context of biologics or tofacitinib; and 6) laboratory monitoring for traditional DMARDs.

METHODS

Overall methodology. We developed this guideline following the recently revised ACR guideline development process (<http://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines>). This process includes the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology (available at www.gradeworkinggroup.org) (7–9).

Teams involved. A Core Leadership Team (see Appendix A for a list of Panel and Team members) supervised the project and was responsible for defining the project scope, drafting the clinical questions to be addressed by the guideline, coordinating with the Literature Review Team's efforts, and drafting the manuscript based on vot-

sulting fees, speaking fees, and/or honoraria from Pfizer, Bristol-Myers Squibb, Crescendo, and AbbVie (less than \$10,000 each) and from Roche/Genentech, UCB, Janssen, the Consortium of Rheumatology Researchers of North America (CORRONA) registry, and Amgen (more than \$10,000 each). Dr. Furst has received consulting fees, speaking fees, and/or honoraria from AbbVie, Actelion, Amgen, Bristol Myers Squibb, Cytos, Janssen, Gilead, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, and UCB (less than \$10,000 each) and has received research support from AbbVie, Actelion, Amgen, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Pfizer, Roche/Genentech, and UCB. Dr. Kavanaugh has received consulting fees, speaking fees, and/or honoraria from Amgen, AbbVie, and Pfizer (less than \$10,000 each) and grant/research support from Amgen, AbbVie, Bristol-Myers Squibb, Janssen, UCB, Roche, and Pfizer. Dr. O'Dell has received consulting fees, speaking fees, and/or honoraria from Medac, Antares, AbbVie, Bristol-Myers Squibb, and Lilly (less than \$10,000 each). Dr. King receives indirect sponsor payments as Medical Director of the North Mississippi Arthritis and Research Center. Ms Leong has received consulting fees, speaking fees, and/or honoraria from Horizon, GlaxoSmithKline, and Zimmer (less than \$10,000 each). Dr. Matteson receives royalties from UpToDate, and has received grant/research support from Roche, Genentech, Mesoblast, Ardea, Novartis, Sanofi, Centocor, Janssen, Celgene, UCB, and GlaxoSmithKline. Dr. Grober has received consulting fees, speaking fees, and/or honoraria from Medac (less than \$10,000). Dr. St.Clair owns stock or stock options from Bristol-Myers Squibb, Merck, and Proctor & Gamble, receives royalties from UpToDate, and has received grant/research support from Biogen. Dr. McAlindon has received consulting fees, speaking fees, and/or honoraria from Sanofi-Aventis, Samumed, Fidia, Flexion, and McNeil Consumer Healthcare (less than \$10,000 each) and has a patent on an online clinical trial methodology through Boston University Medical School.

Address correspondence to Jasvinder A. Singh, MBBS, MPH, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: jasvinder.md@gmail.com.

Submitted for publication March 19, 2015; accepted in revised form October 14, 2015.

ing by a panel (described below). The Core Leadership Team was led by a chair (JAS) who possessed both content and methodologic expertise. The Core Leadership Team also included a methodologist (EAA), who advised on the process and provided input on the GRADE summary of findings tables (see Evidence Report as part of Supplementary Appendix 1 available on the *Arthritis Care & Research* web site at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>), and experts in guideline development. A Literature Review Team (see Appendix A for a list of Panel and Team members) conducted the literature review, graded the quality of evidence, developed the summary of findings tables, and produced an evidence report. A Content Panel, composed of 4 content experts (see Appendix A for a list of Panel and Team members) reviewed and provided feedback on the clinical questions and the evidence report, and provided consultation throughout the project. Finally, a Voting Panel (see Appendix A for a list of Panel and Team members) helped determine which clinical questions would be asked and which outcomes were critical, and they voted on the final recommendations after reviewing the evidence provided by the Literature Review Team. The Voting Panel included rheumatologists with expertise and clinical experience in treating RA (AK, JOD, CK, ELM, JTS, BD, JG, EWSC, ET), as well as 2 patient representatives (AL, SG). Training was conducted with all members of the guideline development group to prepare them for their roles, including specific sessions on the ACR guideline process and GRADE methodology.

Disclosures and management of conflicts of interest. In accordance with ACR policy, everyone who was intellectually involved in the project (i.e., considered for guideline authorship) disclosed all relationships in writing at the beginning, middle, and end of the project. Disclosures were compared against a previously drafted list of “affected companies” (i.e., companies or organizations that were considered reasonably likely to be positively or negatively affected by care delivered in accordance with the guideline) to determine which relationships were considered conflicts of interest for purposes of this project. Individuals whose primary employment (>51% of work time/effort) was with a company that manufactured or sold therapeutics or diagnostics were not eligible to participate.

The project Principal Investigator (JAS) and Literature Review Team Leader (TM) had no relevant conflicts of interest for the full 12 months before this project began, and a majority (>51%) of all guideline development team members, including the Principal Investigator and Literature Review Team Leader, had no relevant conflicts of interest for the duration of the project. A participant who had any relationship with an affected company was counted as conflicted (i.e., toward the allowed threshold) regardless of the type or subject of the relationship. Intellectual conflicts, such as a prior publication or presentation on an RA therapeutic, were recognized as important and were required to be disclosed, but because they were ubiquitous, participants with intellectual conflicts were not counted as conflicted (i.e., toward the allowed threshold) based on their intellectual conflict alone.

Participant disclosures were included in the project plan that was posted online for public comment (see description below). In addition, disclosures of all participants were shared with each project participant in writing. At the face-to-face Voting Panel meeting, verbal disclosures were provided before any content discussion. Updated participant disclosures, as well as ACR committee reviewer disclosures, are available online (www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Rheumatoid-Arthritis). Author disclosures are detailed in the footnotes of this article.

Scope and target audience. The Core Leadership Team decided that the guideline would address topics concerning the treatment of RA and not address any topics related to diagnosis, monitoring of disease activity, surgical interventions, or physical therapy interventions. The target audience includes both clinicians and their patients with RA. The ACR plans to develop derivative products in the future, including a pocket card, an app version of this guideline, and a patient education tool to facilitate implementation.

Establishing key principles and PICO (population, intervention, comparator, and outcomes) development. Key principles and provisos, key terms, descriptions, and drug categories used in the guideline development process are shown in Table 1. These key principles were first reviewed by the Content Panel and the Core Leadership Team. The key principles were then provided to the Voting Panel when they reviewed the drafted evidence report, and also when they discussed and voted on each recommendation. The Core Leadership Team collaborated with the Content Panel to develop the initial set of PICO-formatted clinical questions for the guideline (10). We considered clinically relevant interventions and comparators after extensive discussion with the Content Panel and the Core Leadership Team, balancing comprehensiveness with feasibility. These PICO questions were posted for 30 days on the ACR web site for public comment, and revised accordingly. The final set of PICO questions addressed the 6 major topics listed above.

Systematic synthesis of the literature. *Literature searches.* We performed systematic searches of the published literature to identify relevant evidence for the PICO questions (11). Study designs in the literature review included systematic reviews, randomized controlled trials (RCTs), and observational studies (including case series). We searched OVID Medline, PubMed, Embase, and the Cochrane Library (including Cochrane Database of Systematic Reviews; Database of Abstracts of Reviews of Effects; Cochrane Central Register of Controlled Trials; and Health Technology Assessments) (see Supplementary Appendix 2 available on the *Arthritis Care & Research* web site at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>) (11). The searches were performed using database-specific subject headings and keywords related to the following domains of interest: RA, traditional/conventional DMARDs, tumor necrosis factor inhibitor (TNFi) biologics (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), non-TNF biologics (abatacept, rituximab, or tocilizumab), tofacitinib, glucocorticoids, and adverse events. We limited our searches to adults ages

Table 1. Key provisos and principles, key terms, definitions, and drug categories for the 2015 ACR recommendations for the treatment of rheumatoid arthritis*

Key provisos and principles	
<ol style="list-style-type: none"> 1. Focus on common clinical scenarios, not exceptional cases. 2. Cost is a consideration in these recommendations; however, explicit cost-effectiveness analyses were not conducted. 3. Disease activity measurement using an ACR-recommended measure should be performed in a majority of encounters for RA patients (16).† 4. Functional status assessment using a standardized, validated measure should be performed routinely for RA patients, at least once per year, but more frequently if disease is active. Examples of commonly used functional status measures include Health Assessment Questionnaire, Health Assessment Questionnaire II, Multidimensional Health Assessment Questionnaire, PROMIS (available at https://www.assessmentcenter.net/) Physical Function 10-item, PROMIS Physical Function 20-item, and PROMIS Physical Function Computerized Adaptive Tests (PROFPCAT). 5. If a patient has low RA disease activity or is in clinical remission, switching from one therapy to another should be considered only at the discretion of the treating physician in consultation with the patient. <i>Arbitrary switching between RA therapies based only on a payer/insurance company policy is not recommended.</i> 6. A treatment recommendation favoring one medication over another means that the preferred medication would be the recommended first option. However, favoring one medication over the other does not imply that the nonfavored medication is contraindicated for use in that situation; it may still be a potential option under certain conditions. 	
Key terms	Definitions
Adult RA patient	Adults, ≥18 years, meeting the ACR RA classification criteria (1987 or 2010 revised criteria) (81,82).
Health benefits and harms	Efficacy and safety of treatments including desirable and undesirable effects.
Early RA	RA with duration of disease/symptoms of <6 months, where “duration” denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis.
Established RA	RA with duration of disease/symptoms of ≥6 months <u>or</u> meeting 1987 ACR RA classification criteria (81).‡
Disease activity	Categorized as low, moderate, or high as per validated scales (Table 2) (144–150). Moderate and high disease activity categories were combined based on feedback from the Content Panel, as used previously for the 2012 ACR RA treatment recommendations.
RA remission	A joint ACR/EULAR task force defined remission as a tender joint count, swollen joint count, C-reactive protein level (mg/dl), and patient global assessment of ≤1 each or a Simplified DAS of ≤3.3 (151), 1 of 6 ACR-endorsed disease activity measures.†
Optimal dosing of RA treatments	1) Dosing to achieve a therapeutic target derived from mutual patient-clinician consideration of patient priorities, and 2) given for at least 3 months before therapy escalation or switching.
DMARD failure	Failure of traditional/conventional DMARD(s) due to lack of efficacy/desired response or side effects.
Biologic failure	Failure of biologic(s) due to lack of efficacy/desired response or side effects.
Secondary biologic failure	Biologic was efficacious initially but subsequently became inefficacious.
Active hepatitis B infection	Hepatitis B surface antigen positive, hepatitis B surface antibody negative, hepatitis B core antibody total positive (less important), AST/ALT typically increased, HBV DNA positive (if checked).
Hepatitis C infection	HCV antibody positive, HCV RNA positive, AST/ALT typically increased.
NYHA class III and IV	NYHA class III includes patients with cardiac disease resulting in marked limitation of physical activity with less than ordinary physical activity causing fatigue, palpitation, dyspnea, or angina, but no symptoms at rest. NYHA class IV includes patients with cardiac disease resulting in inability to carry on any physical activity without discomfort, symptoms of heart failure are present even at rest, and discomfort increases if any physical activity is undertaken (152).
Drug category	Descriptions
Methotrexate	Used either oral or subcutaneous (a DMARD).
DMARDs§	Traditional/conventional DMARDs including HCQ, LEF, MTX, or SSZ (excludes azathioprine, cyclosporine, minocycline and gold), it does not include tofacitinib, which is considered separately.¶
DMARD monotherapy	Most often defined as the use of MTX monotherapy, but may also be SSZ, HCQ, or LEF.
Double DMARD therapy	MTX+SSZ, MTX+HCQ, SSZ+HCQ, or combinations with LEF.

(continued)

Table 1. (Cont'd)

Drug category	Descriptions
Triple DMARD therapy	MTX+SSZ+HCQ.
DMARD combination therapy	Double or triple traditional/conventional DMARD therapy.
Tofacitinib	Oral synthetic small molecule.
Biologics	TNFi biologic or non-TNF biologic (excludes anakinra).§
TNFi biologics	Adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab.
Non-TNF biologics	Abatacept, rituximab, or tocilizumab (excludes anakinra).§
Low-dose glucocorticoid	≤10 mg/day of prednisone (or equivalent).
High-dose glucocorticoid	>10 mg/day of prednisone (or equivalent) and up to 60 mg/day with a rapid taper.#
Short-term glucocorticoid	<3 month treatment.

* ACR = American College of Rheumatology; RA = rheumatoid arthritis; PROMIS = Patient-Reported Outcomes Measurement Information System; EULAR = European League Against Rheumatism; DAS = Disease Activity Score; DMARD = disease-modifying antirheumatic drug; AST = aspartate aminotransferase; ALT = alanine aminotransferase; HBV = hepatitis B virus; HCV = hepatitis C virus; NYHA = New York Heart Association; HCQ = hydroxychloroquine; LEF = leflunomide; MTX = methotrexate; SSZ = sulfasalazine; TNFi = tumor necrosis factor inhibitor; COBRA = Combinatie-therapie Bij Reumatoide Artritis.

† Any of the ACR recommended disease activity measures may be chosen, as described in ref. 16.

‡ New classification criteria for RA (ACR/EULAR collaborative initiative) were published in 2010 (82), the definition of established RA is based on the 1987 ACR RA classification criteria, since the 2010 ACR RA classification allows a much earlier diagnosis.

§ Anakinra was considered but not included in these guidelines due to its infrequent use in RA and lack of new data since 2012.

¶ Azathioprine, cyclosporine, minocycline and gold were considered but not included in these guidelines due to their infrequent use in RA and/or lack of new data since 2012.

Regimen based on that described in the COBRA study (153).

≥18 years and to English language publications. Duplicate references were removed. We excluded narrative reviews, editorials, scientific conference abstracts, and case reports.

The literature related to treatment modalities covered by past ACR RA guidelines (i.e., traditional/conventional DMARDs, TNFi and non-TNF biologics) and tofacitinib was searched to include articles published from January 1, 2009 through March 3, 2014. For other treatment modalities not covered by past ACR RA guidelines (i.e., glucocorticoids), we searched the databases from inception until March 3, 2014. We updated initial literature searches on September 17, 2014. All searches were developed by a medical librarian in collaboration with the Literature Review Team and were peer reviewed by a second medical librarian.

Study selection. The literature search results underwent primary screening in DistillerSR software (Evidence Partners). During primary literature screening, 2 reviewers (various pairs, made from a pool of reviewers including authors MCS, EV, CM, and MO, as well as the medical librarian) independently reviewed the title and abstract of each article for potential eligibility. A third reviewer (RRB) resolved conflicts regarding inclusion versus exclusion. Articles judged as potentially eligible were tagged for electronic matching to specific PICO questions, and subsequently underwent full-text article screening. Each full text was screened by 2 reviewers and independently tagged with PICO-matching criteria. A secondary hand sorting of all randomized studies was conducted to ensure successful matching of relevant evidence to PICO questions (for details on the study selection see Supplementary Appendix 3 available on the *Arthritis Care & Research* web site at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>).

Data extraction and analysis. We extracted study data for each PICO question into RevMan software (12). When determining which data to include, we followed the GRADE methodology that gives preference to RCTs over observational studies as the highest-quality source of evidence. Whenever

er data from both randomized and observational trials were available, and the RCT was of high quality, we extracted RCT data only (13). A RevMan file was created for each PICO question, and data were pooled and analyzed using this software. Continuous outcome variables were analyzed using the inverse variance method in a random effects model. Continuous outcomes were reported as mean differences with 95% confidence intervals; standardized mean differences (similar in concept to effect sizes) were used when the outcome was measured with different scales. Dichotomous variables were analyzed using the Mantel-Haenszel method in a random effects model. These variables were reported as risk ratios with 95% confidence intervals.

Quality assessment and evidence report formulation. We exported RevMan analyses into GRADEpro software to formulate a GRADE summary of findings table for each PICO question. The quality of evidence, such as the confidence in the effect estimates for each outcome, was evaluated based on GRADE quality assessment criteria. Two independent reviewers (RRB, MCS) performed this GRADE quality assessment in duplicate and discordance was resolved by consensus. This included the risk of bias in included trials, the likelihood of publication bias, inconsistency between trial results, indirectness of the evidence (e.g., differences between populations, interventions, or outcomes of interest in the group to whom the recommendation applies versus those who were included in the studies referenced), and imprecision (wide confidence intervals, usually due to a small number of patients or events, or those situations where clinical decision-making would differ at the extremes of the confidence interval).

The GRADE method distinguishes 4 levels of quality of evidence based on the degree of confidence that the pooled effect estimate lies close to the true effect. Thus, the quality of evidence for each outcome could be rated as high, moderate, low, or very low. The overall evidence quality grade was the lowest quality rating among the individual outcomes deemed

	Strong recommendation	Conditional recommendation
Patients	Most people in your situation would want the recommended course of action and only a small proportion would not	<i>The majority of people in your situation would want the recommended course of action, but many would not*</i>
Clinicians	Most patients should receive the recommended course of action	<i>Be prepared to help patients to make a decision that is consistent with their own values</i>
Policy makers	The recommendation can be adapted as a policy in most situations	<i>There is a need for substantial debate and involvement of stakeholders</i>

Figure 1. Implications of strong and conditional GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology recommendations (154). * = majority means >50% of the people.

critical for the comparison between interventions (14). In the absence of any data, the level of evidence was rated as very low, because it was based on clinical experience only.

We compiled the resulting summary of findings tables in an evidence report (see Supplementary Appendix 1, <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>) that was accompanied by a qualitative summary of the evidence for each PICO question. The Content Panel reviewed the drafted evidence report and revised the report to address evidence gaps prior to presentation to the Voting Panel. We referred to other society/organization guidelines for topics that do not exclusively relate to rheumatologic care, such as liver disease (American Association for the Study of Liver Diseases [AASLD]) and TB screening and immunization (Centers for Disease Control and Prevention [CDC]).

Moving from evidence to recommendations. Each recommendation was made based on a consideration of the balance of relative benefits and harms of the treatment options under consideration, the quality of the evidence (i.e., confidence in the effect estimates), and patients' values and preferences, as per GRADE methodology.

A recommendation could be either in favor of or against the proposed intervention and either strong or conditional. According to GRADE, a recommendation is categorized as strong if the panel is very confident that the benefits of an intervention far outweigh the harms (or vice versa) (7–9) (Figure 1). A conditional recommendation denotes uncertainty over the balance of benefits and harms, such as when the evidence quality is low or very low, or when patient preferences or costs are expected to impact the decision. Thus, conditional recommendations refer to decisions where incorporation of patient preferences is an essential element of decision making.

Consensus building. The Voting Panel received the evidence report for review before it met to discuss and decide on the final recommendations. For each PICO question, the Voting Panel heard an oral summary of the evidence and provided votes on the direction and strength of the related recommendation during a face-to-face meeting held on October 5–6, 2014, and subsequent conference calls and e-mails. The voting process was anonymous and conducted using Poll Everywhere software (available at www.poll.everywhere.com). We used the 70% consensus threshold, which has

been used previously in other similar processes (15) and in previous ACR guidelines (5,6). If 70% consensus was not achieved during an initial vote, the panel members held additional discussions before voting again. In some instances (specifically, DMARD monotherapy failure in early and established RA, hepatitis B, hepatitis C, and previously treated/untreated solid organ cancer), the Voting Panel decided, based on its review of the evidence and its round 1 votes, to combine certain treatment options. They then voted on a new recommendation statement that covered a group of treatment options instead of considering each question separately. In addition, the Voting Panel dropped a number of PICO questions because the clinical scenario was uncommon, irrelevant, or redundant (see Supplementary Appendix 4 available on the *Arthritis Care & Research* web site at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>).

The GRADE methodology contributed a great deal of transparency to the voting process. For example, all of the evidence tables contained detailed descriptions of the criteria upon which the evidence quality was rated (such as estimates of risk of bias or indirectness). As allowed for in GRADE, in some instances, the Voting Panel chose to provide a recommendation in disagreement with the expected strength based on the overall evidence quality (i.e., a strong recommendation despite a low quality rating of evidence). In such cases, a written explanation was provided describing the reasons behind this decision.

Final review and approval of the manuscript by the ACR. In addition to journal peer review, the manuscript was reviewed by the ACR Guideline Subcommittee, ACR Quality of Care Committee, and the ACR Board of Directors, a process that involved over 40 reviewers (details available at www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Rheumatoid-Arthritis). These ACR oversight groups did not mandate that certain recommendations be made within the guideline, but rather, these ACR committees served as peer reviewers.

RESULTS/RECOMMENDATIONS

An abbreviated guideline summary of recommendations for patients with early RA, established RA, and high-risk comorbidities is available (see Executive Summary, Supplementary Appendix 5, available on the *Arthritis*

Table 2. Instruments to measure rheumatoid arthritis disease activity and to define remission*

Instrument (reference)	Thresholds of disease activity
Patient Activity Scale (PAS) or PASII (range 0–10) (149)	Remission: 0–0.25 Low activity: >0.25–3.7 Moderate activity: >3.7 to <8.0 High activity: ≥8.0
Routine Assessment of Patient Index Data 3 (RAPID3) (range 0–10) (155)	Remission: 0–1.0 Low activity: >1.0–2.0 Moderate activity: >2.0–4.0 High activity: >4.0–10
Clinical Disease Activity Index (CDAI) (range 0–76.0) (156)	Remission: ≤2.8 Low activity: >2.8–10.0 Moderate activity: >10.0–22.0 High activity: >22
Disease Activity Score (DAS) 28 erythrocyte sedimentation rate (ESR) (range 0–9.4) (157)	Remission: <2.6 Low activity: ≥2.6 to <3.2 Moderate activity: ≥3.2 to ≤5.1 High activity: >5.1
Simplified Disease Activity Index (SDAI) (range 0–86.0) (158)	Remission: ≤3.3 Low activity: >3.3 to ≤11.0 Moderate activity: >11.0 to ≤26 High activity: >26
* These 6 measures were endorsed by the American College of Rheumatology in 2012 (16). Other measures are now available to clinicians, but they were not included in this guideline because it was beyond the scope of this review. Adapted from ref. 16.	

Care & Research web site at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>).

How to interpret the recommendations

1. Strong recommendations are highlighted in green and bolded, and conditional recommendations are highlighted in yellow and italicized in the figures (Figure 1). A strong recommendation means that the panel was confident that the desirable effects of following the recommendation outweigh the undesirable effects (or vice versa), so the course of action would apply to most patients, and only a small proportion would not want to follow the recommendation. A conditional recommendation means that the desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach.
2. In general, treatment choices are listed in the same order throughout the document (traditional DMARDs, TNFi, non-TNF, tofacitinib), and then alphabetically within each category. When more than one treatment is included as an option, the order does not imply any hierarchy, i.e., each of the treatment options (A or B or C) is recommended equally.

For each recommendation, details regarding the supportive evidence or conditions (for conditional recommendations, but sometimes also for strong recommendations) are summarized in a section titled “Reasoning underlying the recommendations . . .” For example, con-

ditions that the panel considered included comorbidities, patient perception of burden of taking medications, side-effect profile, and cost. Additional details including PICO questions and the GRADE evidence tables are available in Supplementary Appendix 1, <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>).

3. The Voting Panel members agreed to key principles and provisos, key terms, and descriptions prior to voting on the 2015 ACR RA treatment recommendations. These are explicitly stated in Table 1 and apply to the entire guideline. RA disease activity was defined as low, moderate, or high, as previously described (16) (Table 2).

Recommendations for the treatment of patients with early RA

Recommendations for treatment of early RA (disease duration <6 months) patients are provided in Figures 2 and 3. An executive summary of these recommendations is available in Supplementary Appendix 5, <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>.

Reasoning underlying the recommendations for the treatment of early RA. To achieve the above recommendations (Figure 2), the panel discussed several different PICO questions for early RA. The reasoning underlying the recommendations is described below.

PICO A.1. Despite the low quality evidence, the recommendation is **strong** because the Voting Panel concluded that the improved outcomes experienced by patients with established RA using a tar-

Recommendations for patients with symptomatic <u>Early RA</u>	Level of Evidence (evidence reviewed)
1. Regardless of disease activity level, use a treat-to-target strategy rather than a non-targeted approach (PICO A.1).	Low (17)
2. If the disease activity is low, in patients who have never taken a DMARD: <ul style="list-style-type: none"> • use DMARD monotherapy (MTX preferred) over double therapy (PICO A.2). • use DMARD monotherapy (MTX preferred) over triple therapy (PICO A.3). 	Low (18-21) Low (22-25)
<i>3. If the disease activity is moderate or high, in patients who have never taken a DMARD:</i> <ul style="list-style-type: none"> • use DMARD monotherapy over double therapy (PICO A.4). • use DMARD monotherapy over triple therapy (PICO A.5). 	<i>Moderate (18,20,21)</i> <i>High (22-25)</i>
4. If disease activity remains moderate or high despite DMARD monotherapy (with or without glucocorticoids), use combination DMARDs or a TNFi or a non-TNF biologic (all choices with or without MTX, in no particular order of preference), rather than continuing DMARD monotherapy alone (PICO A.7).	Low (26-28)
<i>5. If disease activity remains moderate or high despite DMARDs:</i> <ul style="list-style-type: none"> • use a TNFi monotherapy over tofacitinib monotherapy (PICO A.8). • use a TNFi + MTX over tofacitinib + MTX (PICO A.9). 	<i>Low (29)</i> <i>Low (30)</i>
<i>6. If disease activity remains moderate or high despite DMARD (PICO A.6) or biologic therapies (PICO A.12), add low-dose glucocorticoids.</i>	<i>Moderate (31-37)</i> <i>Low (31-37)</i>
<i>7. If disease flares, add short-term glucocorticoids at the lowest possible dose and for the shortest possible duration (PICO A.10, A.11).</i>	<i>Very low (38-43)</i>

Figure 2. Summary of 2015 American College of Rheumatology recommendations for the treatment of Early rheumatoid arthritis (RA). Green and bolded = strong recommendation. A strong recommendation means that the panel was confident that the desirable effects of following the recommendation outweigh the undesirable effects (or vice versa), so the course of action would apply to most patients, and only a small proportion would not want to follow the recommendation. Yellow and italicized = conditional recommendation: The desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach. A treatment recommendation favoring one medication over another means that the preferred medication would be the recommended first option and the nonpreferred medication may be the second option. Favoring one medication over the other does not imply that the nonfavored medication is contraindicated for use; it is still an option. Therapies are listed alphabetically; azathioprine, gold, and cyclosporine were considered but not included. Disease-modifying antirheumatic drugs (DMARDs) include hydroxychloroquine, leflunomide, methotrexate (MTX), and sulfasalazine. PICO = population, intervention, comparator, and outcomes; TNFi = tumor necrosis factor inhibitor. For definitions and descriptions, see Table 1.

geted approach should be generalizable to those with early RA (Figure 2).

PICOs A.2 and A.3. Despite the low quality evidence, the recommendation is **strong** because 1) there is no evidence in favor of triple therapy in this setting, 2) DMARD monotherapy is generally more acceptable (i.e., easier to take, less cost to the patient) to early RA patients with low disease activity than DMARD combination regimens, and 3) DMARD monotherapy is generally better tolerated than combination DMARD therapy. The panel also voted that methotrexate (MTX) should be the preferred initial DMARD for most early RA patients.

PICOs A.4 and A.5. The recommendation is *conditional* because 1) the evidence is of low quality and the evidence for differences in side effects is imprecise, 2) there is little difference in the benefit of double DMARD therapy over monotherapy, and 3) triple therapy might be preferred by some patients who desire a more rapid short-term benefit

(e.g., earlier resumption of work activities) and are willing to assume potential added risk.

PICOs A.6 and A.12. The recommendation is *conditional* because 1) the evidence is of low quality, and 2) although glucocorticoid therapy is effective as a short-term (i.e., less than 3 months) therapy to “bridge” patients until realizing the benefits of DMARDs, this decision must be balanced by the lack of long-term glucocorticoid safety studies. The risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and the duration of therapy is short.

PICO A.7. The recommendation is **strong** despite the low quality of evidence because, for a patient failing DMARD monotherapy, clinical experience and indirect evidence support the benefits of adding these treatment options, and recommending no additional treatment is not an option. When deciding which therapy to use, considerations may include cost, comorbidities, burden of taking medications (i.e., 1 versus multiple, oral versus other routes) and side-effect profile. The panel also voted that biologic therapy should




Figure 3. 2015 American College of Rheumatology recommendations for the treatment of Early rheumatoid arthritis (RA), defined as disease duration <6 months. * = consider adding low-dose glucocorticoids (≤ 10 mg/day of prednisone or equivalent) in patients with moderate or high RA disease activity when starting disease-modifying antirheumatic drugs (DMARDs) and in patients with DMARD failure or biologic failure. † = also consider using short-term glucocorticoids (defined as <3 months treatment) for RA disease flares. Glucocorticoids should be used at the lowest possible dose and for the shortest possible duration to provide the best benefit-risk ratio for the patient. # = treatment target should ideally be low disease activity or remission. For the level of evidence supporting each recommendation, see the related section in the Results. This figure is derived from recommendations based on PICO (population, intervention, comparator, and outcomes) questions A.1 to A.12. For definitions of disease activity (categorized as low, moderate, or high) and descriptions, see Tables 1 and 2. MTX = methotrexate.

be used in combination with MTX, when possible, due to superior efficacy of this combination over biologic monotherapy.

PICOs A.8 and A.9. The recommendation is *conditional* because 1) the evidence is low quality, and 2) there are potential longer-term safety concerns related to tofacitinib that need more study, partly related to the shorter experience using tofacitinib.

PICOs A.10 and A.11. The recommendation is *conditional* because the evidence is of low quality because it is indirect, and the risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and duration of therapy is short.

Recommendations for the treatment of patients with established RA

Recommendations for treatment of established RA patients (disease duration ≥ 6 months), including tapering therapy, are provided in Figures 4 and 5. An executive summary of these recommendations is available in Supplementary Appendix 5, <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>.

Reasoning underlying the recommendations for the treatment of established RA

PICO B.1. The recommendation is **strong** because, based on moderate quality evidence, the panel concluded that the benefits far outweigh the risks for patients with established RA treated with a targeted approach compared to a non-targeted approach (Figure 4).

PICO B.2. The recommendation is **strong** despite the low quality of evidence because DMARD monotherapy is available as a less costly first-line therapy that has an extensive safety record with well-documented clinical efficacy, a large body of clinical experience, and familiarity among rheumatologists. The panel also voted that MTX should be the preferred initial DMARD for most patients with established RA who have never taken a DMARD.

PICO B.3. The recommendation is *conditional* despite the published positive tofacitinib efficacy data because the balance of benefit (tofacitinib slightly more efficacious), risk (long-term safety of tofacitinib is currently not well-known versus the well-known long-term safety of MTX), and cost considerations (MTX is less expensive than tofacitinib), favored MTX overall.

PICO B.4. The recommendation is *conditional* because the evidence is of low quality. The evidence supporting an incremental benefit for double DMARD therapy over DMARD monotherapy is indirect, and the evidence for differences in side effects is imprecise.

PICO B.5. The recommendation is **strong** despite moderate to very low quality of evidence because for

a patient failing DMARD monotherapy, clinical experience and indirect evidence support the benefits of adding these treatment options, and recommending no treatment is not an option. The panel also voted that biologic therapy should be used in combination with MTX, when possible, due to superior efficacy of this combination over biologic monotherapy.

PICO B.6. The recommendation is **strong** because, compared to TNFi monotherapy, TNFi therapy has superior efficacy when used in combination with MTX, based on high quality evidence.

PICOs B.12 and B.14. The recommendation is *conditional* because 1) there is evidence for rituximab's efficacy in patients who have already received TNFi therapy, and for tocilizumab's superiority over a TNFi in patients already receiving MTX/DMARDs, and 2) there is evidence for efficacy of tocilizumab monotherapy.

PICOs B.13 and B.15. The recommendation is *conditional* because 1) the evidence is of very low quality, and 2) there is not enough difference in efficacy between non-TNF biologics and tofacitinib to outweigh the long-term safety data and the amount of experience associated with non-TNF biologics.

PICOs B.16 and B.17. The recommendation is *conditional* because 1) the evidence is of very low quality, 2) non-TNF biologics have longer-term safety data compared to tofacitinib, 3) there is greater long-term clinical experience with non-TNF biologics compared to tofacitinib, 4) there is not enough difference in efficacy between non-TNF biologics and tofacitinib to outweigh the longer-term safety data and greater amount of experience with non-TNF biologics, and 5) the fact that other non-TNF biologics with different mechanisms of action may be efficacious and worth trying.

PICOs B.8, B.9, B.10, and B.11. The recommendation is *conditional* because 1) the evidence is of very low quality, and 2) there is limited evidence, especially for the long-term safety data for tofacitinib.

PICOs B.23 and B.24. The recommendation is *conditional* because 1) the evidence is of very low quality, 2) improvement in outcomes as measured by the Health Assessment Questionnaire is numerically higher for patients randomized to tofacitinib compared to TNFi in an RCT; however, long-term safety data for tofacitinib are not yet available, and 3) some patients may prefer an oral formulation over an injection.

PICOs B.21 and B.22. The recommendation is *conditional* for the same reasons as cited above for PICOs B.16 and B.17 (except reason #2).

PICOs B.19 and B.20. The recommendation is *conditional* for the same reasons as cited above for PICOs B.23 and B.24.

Recommendations for patients with Established RA ¹	Level of Evidence (evidence reviewed)
1. Regardless of disease activity level, use a treat-to-target strategy rather than a non-targeted approach (PICO B.1).	Moderate (44-46)
2. If the disease activity is low, in patients who have never taken a DMARD, use DMARD monotherapy (MTX preferred) over a TNFi (PICO B.2).	Low (47,48)
3. If the disease activity is moderate or high in patients who have never taken a DMARD: <ul style="list-style-type: none"> • use DMARD monotherapy (MTX preferred) over tofacitinib (PICO B.3). • use DMARD monotherapy (MTX preferred) over combination DMARD therapy (PICO B.4). 	High (49) Moderate (18,20-25)
4. If disease activity remains moderate or high despite DMARD monotherapy, use combination traditional DMARDs <u>or</u> add a TNFi <u>or</u> a non-TNF biologic <u>or</u> tofacitinib (all choices with or without MTX, in no particular order of preference), rather than continuing DMARD monotherapy alone (PICO B.5).	Moderate to Very low (23,26,29,30,47,48,50-59)
5. If disease activity remains moderate or high despite TNFi therapy in patients who are currently not on DMARDs, add one or two DMARDs to TNFi therapy rather than continuing TNFi therapy alone (PICO B.6).	High (60-65)
6. If disease activity remains moderate or high despite use of a single TNFi: <ul style="list-style-type: none"> • use a non-TNF biologic, with or without MTX, over another TNFi with or without MTX (PICO B.12 and B.14). • use a non-TNF biologic, with or without MTX, over tofacitinib with or without MTX (PICO B.13 and B.15). 	Low to Very low (66-72) Very low ⁴
7. If disease activity remains moderate or high despite use of a single non-TNF biologic, use another non-TNF biologic, with or without MTX, over tofacitinib, with or without MTX (PICO B.16 and B.17).	Very low ⁴
8. If disease activity remains moderate or high despite use of multiple (2+) sequential TNFi therapies, first use a non-TNF biologic, with or without MTX, over another TNFi or tofacitinib (with or without MTX) (PICO B.8, B.9, B.10, B.11).	Very low (73-75)
9. If the disease activity still remains moderate or high despite the use of multiple TNFi therapies, use tofacitinib, with or without MTX, over another TNFi, with or without MTX, if use of a non-TNF biologic is not an option (PICO B.23 and B.24).	Low (29,30)
10. If disease activity remains moderate or high despite use of at least one TNFi and at least one non-TNF-biologic: <ul style="list-style-type: none"> • first use another non-TNF biologic, with or without MTX, over tofacitinib (PICO B.21 and B.22). • If disease activity remains moderate or high, use tofacitinib, with or without MTX, over another TNFi (PICO B.19 and B.20). 	Very low (29,30) Very low (29)
11. If disease activity remains moderate or high despite use of DMARD, TNFi, or non-TNF biologic therapy, add short-term, low dose glucocorticoid therapy (PICO B.26 and B.27).	High to Moderate (33,41,76,77)
12. If disease flares in patients on DMARD, TNFi, or non-TNF biologic therapy, add short-term glucocorticoids at the lowest possible dose and the shortest possible duration (PICO B.28 and B.29).	Very low (40-43)
13. If the patient is in remission: <ul style="list-style-type: none"> • taper DMARD therapy (PICO B.31)². • taper TNFi, non-TNF biologic, or tofacitinib (PICO B.33, B.35, B.37) (please also see #15). 	Low ³ (78) Moderate to Very low ³ (79,80)
14. If disease activity is low: <ul style="list-style-type: none"> • continue DMARD therapy (PICO B.30). • continue TNFi, non-TNF biologic or tofacitinib rather than discontinuing respective medication (PICO B.32, B.34 and B.36). 	Moderate (78) High to Very low (79,80)
15. If the patient's disease is in remission, <u>do not</u> discontinue all RA therapies (PICO B.38).	Very low ⁴

Figure 4. Summary of 2015 American College of Rheumatology (ACR) recommendations for the treatment of Established rheumatoid arthritis (RA). Green and bolded = strong recommendation. A strong recommendation means that the panel was confident that the desirable effects of following the recommendation outweigh the undesirable effects (or vice versa), so the course of action would apply to most patients, and only a small proportion would not want to follow the recommendation. Yellow and italicized = conditional recommendation: The desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach. A treatment recommendation favoring one medication over another means that the preferred medication would be the recommended first option and the nonpreferred medication may be the second option. Favoring one medication over the other does not imply that the nonfavored medication is contraindicated for use; it is still an option. Therapies are listed alphabetically; azathioprine, gold, and cyclosporine were considered but not included. Disease-modifying antirheumatic drugs (DMARDs) include hydroxychloroquine, leflunomide, methotrexate (MTX), and sulfasalazine. 1 = definition of established RA is based on the 1987 ACR RA classification criteria (81), since the 2010 ACR/European League Against Rheumatism RA classification allows classification of a much earlier disease state (82). 2 = tapering means scaling back therapy (reducing dose or dosing frequency), not discontinuing it. Tapering should be considered an option and not be mandated. If done, tapering must be conducted slowly and carefully, watching for increased disease activity and flares. Even for patients whose RA is in remission, there is some risk of flare when tapering. 3 = evidence is rated low quality or moderate to very low quality because some evidence reviewed for this recommendation was indirect and included studies with discontinuation rather than tapering of therapy or since studies involved patients achieving low disease activity rather than remission. 4 = no studies were available, leading to very low quality evidence, and the recommendation was based on clinical experience. PICO = population, intervention, comparator, and outcomes; TNFi = tumor necrosis factor inhibitor. For definitions and descriptions, see Table 1.




Figure 5. 2015 American College of Rheumatology (ACR) recommendations for the treatment of Established rheumatoid arthritis (RA), defined as disease duration ≥ 6 months, or meeting the 1987 ACR classification criteria (81). Due to complexity of management of established RA, not all clinical situations and choices could be depicted in this flow chart, and therefore we show the key recommendations. For a complete list of recommendations, please refer to the Results. * = consider adding low-dose glucocorticoids (≤ 10 mg/day of prednisone or equivalent) in patients with moderate or high RA disease activity when starting traditional disease-modifying antirheumatic drugs (DMARDs) and in patients with DMARD failure or biologic failure. † = also consider using short-term glucocorticoids (defined as < 3 months treatment) for RA disease flares. Glucocorticoids should be used at the lowest possible dose and for the shortest possible duration to provide the best benefit-risk ratio for the patient. # = treatment target should ideally be low disease activity or remission. ** = tapering denotes scaling back therapy (reducing dose or dosing frequency), not discontinuing it and if done, must be conducted slowly and carefully. For the level of evidence supporting each recommendation, see the related section in the Results. This figure is derived from recommendations based on PICO (population, intervention, comparator, and outcomes) questions B.1 to B.38. For definitions of disease activity (categorized as low, moderate, or high) and descriptions, see Tables 1 and 2. MTX = methotrexate; TNFi = tumor-necrosis factor inhibitor.

Table 3. Recommendations for optimal followup laboratory monitoring intervals for complete blood count, liver transaminase levels, and serum creatinine levels for patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs*

Therapeutic agents†	Monitoring interval based on duration of therapy‡		
	<3 months	3–6 months	>6 months
Hydroxychloroquine	None after baseline§	None	None
Leflunomide	2–4 weeks	8–12 weeks	12 weeks
Methotrexate	2–4 weeks	8–12 weeks	12 weeks
Sulfasalazine	2–4 weeks	8–12 weeks	12 weeks

* More frequent monitoring is recommended within the first 3 months of therapy or after increasing the dose, and the outer bound of the monitoring interval is recommended beyond 6 months of therapy. Adapted from ref. 6.
† Listed alphabetically.
‡ The panel indicated that patients with comorbidities, abnormal laboratory results, and/or multiple therapies may require more frequent laboratory testing than what is generally recommended laboratory monitoring for disease-modifying antirheumatic drugs in the table.
§ See ref. 6 for baseline monitoring recommendations.

PICOs B.26 and B.27. The recommendation is *conditional* because the risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and duration of therapy is short.

PICOs B.28 and B.29. The recommendation is *conditional* because 1) the evidence is of very low quality, and 2) the risk/benefit ratio of glucocorticoid therapy is favorable as long as the dose is low and duration of therapy is short.

The panel also made several recommendations related to tapering therapy, with the following general caveats: 1) “Tapering” is defined as scaling back therapy 1 medication at a time (reducing dose or dosing frequency), 2) Patients’ values and preferences should drive decisions related to tapering, 3) A comprehensive plan to monitor disease activity and address possible flares is implemented, and 4) Prior to tapering, RA patients, including those in sustained remission, are informed of the risk of flare.

PICOs B.31, B.33, B.35, and B.37. The recommendation is *conditional* because 1) the evidence is of low quality, 2) while tapering carries a risk of flare, minimizing therapy may decrease toxicity, and/or cost, and lowers the risk of treating patients unnecessarily.

PICOs B.30, B.32, B.34, and B.36. The recommendation is **strong** because based on clinical observations and experience only a small minority of patients with low disease activity (not remission) is able to successfully discontinue all RA therapy.

PICO B.38. The recommendation is **strong** despite very low quality of evidence because based on clinical experience, the risk of RA flare and the need for resumption of therapy are high, if all RA therapies are discontinued.

The Voting Panel also voted on 2 additional PICO questions (B.7 and B.18) to fill the remaining gaps in the treatment algorithm after the initial voting (Figure 5). Both compare therapy with no therapy. We followed the GRADE methodology and the same process for these PICO questions.

PICO B.7. If disease activity remains moderate or high despite the use of a single TNFi, the recommendation is *conditional* for using another TNFi rather than not using a TNFi. The recommendation is *conditional* because both evidence from TNFi studies and clinical experience support response to a second TNFi in a significant proportion of patients, especially in the presence of secondary failure (i.e., a TNFi worked initially and then stopped working). For additional recommendations related to this patient population, see PICOs B.12, B.15, B.23, and B.24.

PICO B.18. If disease activity remains moderate or high despite the use of multiple non-TNF biologics and the patient is TNFi-naïve, the recommendation is *conditional* for using TNFi rather than not using TNFi. The recommendation is *conditional* because the evidence is of very low quality. Although there are no trials of patients with multiple non-TNF biologic failures, if non-TNF biologics have not been effective and TNFi therapy has not yet been given, then TNFi therapy should be tried, unless there are contraindications for its use.

Recommendations for laboratory monitoring for DMARDs and TB screening in patients receiving biologics or tofacitinib

The panel endorsed the recommendations previously published in the 2008 recommendations and in the 2012 update to be included in the 2015 recommendations (Table 3 and Figure 6). The panel indicated that in the absence of significant new knowledge, development of an alternate rec-




Figure 6. Tuberculosis (TB) screening algorithm for biologics or tofacitinib (endorsed and modified from the 2012 American College of Rheumatology RA treatment recommendations). The Voting Panel reviewed and endorsed the 2012 TB screening algorithm with 1 change, that tofacitinib should be included alongside biologics. * = anergy panel testing is not recommended. ** = interferon-gamma release assay (IGRA) is preferred if patient has a history of BCG vaccination. † = risk factors for TB exposure are defined based on a publication from the US Centers for Disease Control and Prevention as: close contacts of persons known or suspected to have active TB, foreign-born persons from areas that have a high incidence of active TB (e.g., Africa, Asia, Eastern Europe, Latin America, and Russia), persons who visit areas with a high prevalence of active TB, especially if visits are frequent or prolonged, residents and employees of congregate settings whose clients are at increased risk for active TB (e.g., correctional facilities, long-term care facilities, and homeless shelters), health care workers who serve clients who are at increased risk for active TB, populations defined locally as having an increased incidence of latent *Mycobacterium tuberculosis* infection or active TB, possibly including medically underserved, low-income populations, or persons who abuse drugs or alcohol, and infants, children, and adolescents exposed to adults who are at increased risk for latent *M. tuberculosis* infection or active tuberculosis (159,160). †† = if patient is immunosuppressed and false-negative results more likely, consider repeating screening test(s) with tuberculin skin test (TST) or IGRA. § = chest radiography may also be considered when clinically indicated in patients with risk factors, even with a negative result on repeat TST or IGRA. # = obtain respiratory (e.g., sputum, bronchoalveolar lavage) or other samples as clinically appropriate for acid-fast bacilli (AFB) smear and culture. Consider referral to TB specialist for further evaluation and treatment. ¶ = in a patient diagnosed as having latent or active TB, consider referral to a specialist for the recommended treatment. ^ = patients who test positive for TST or IGRA at baseline (pretreatment) often remain positive for these tests even after successful treatment of TB. These patients need monitoring for clinical signs and symptoms of recurrent TB disease, since repeating tests will not allow help in diagnosis of recurrent TB. The level of evidence supporting each recommendation for TB reactivation was derived from consensus opinion of experts, case studies, or standards of care. The level of evidence for initiation of biologics in patients being treated for latent TB infection was higher, with data derived from a single randomized trial or nonrandomized studies. Adapted from ref. 5.

ommendation was not warranted with one exception: the Voting Panel recommended that the same TB screening algorithm as described for biologics should be followed for patients receiving tofacitinib. For additional details (including baseline laboratory monitoring), please see the 2008 and 2012 guidelines (5,6).

Recommendations in RA patients with high-risk comorbidities

Recommendations are provided in Figure 7. An executive summary of these recommendations is available in Supplementary Appendix 5, <http://onlinelibrary.wiley.com/doi/10.1002/acr.22783/abstract>.

Congestive heart failure

PICOs C.1, C.2, C.3, C.4, C.5, and C.6. The recommendations are *conditional* because the evidence is of very low quality. The Voting Panel noted that there are no reports of exacerbation of heart failure using non-TNF biologics and the US Food and Drug Administration (FDA) warns against using TNFi in this population based on worsening of congestive heart failure with TNFi in the Adverse Event Reporting System database. A TNFi should only be used if there are no other reasonable options, and then, perhaps, only in compensated heart failure (83,84) (Figure 7).

Hepatitis B

To address hepatitis B, the AASLD practice guidelines were reviewed (85,86). These guidelines suggest that immunosuppressive therapy can be safely utilized when prophylactic antiviral therapy is prescribed concomitantly.

PICO D.1. The recommendation is **strong** despite very low evidence (85–92) because clinical experience supports the benefits of treating these RA patients with active disease, and an absence of additional harms, if patients are receiving concomitant effective antiviral treatment. The Voting Panel further specified that for a patient with natural immunity from prior exposure to hepatitis B (i.e., hepatitis B core antibody positive, normal liver function tests, and hepatitis B surface [HBs] antibody positive and HBs antigen negative), RA treatment should be the same as that of unexposed patients, as long as the patient's viral load is monitored regularly (117,118), conservatively, every 6–12 months. For patients with chronic hepatitis B who are untreated, referral for antiviral therapy is appropriate prior to immunosuppressive therapy (88,119–124). A recent review summarized this evidence (125).

Hepatitis C

PICO E.1. The recommendation is *conditional* because the evidence is of very low quality, i.e., indirect evidence from patient populations other

than RA (92–103). The evidence suggests that these RA patients with hepatitis C virus (HCV) infection should *not* be treated differently than RA patients who do not have hepatitis C. The Voting Panel recommended that rheumatologists collaborate with gastroenterologists and/or hepatologists to monitor patients receiving antiviral therapy. This is important considering the recent availability of highly effective therapy for HCV, which might lead to a greater number of HCV patients being treated successfully.

PICO E.2. The recommendation is *conditional* because the evidence is of very low quality. For patients with HCV infection or exposure, the safety of biologic therapy was addressed indirectly by 2 RCTs and a variety of small observational studies including case series (92–103). Much of this research was not confined to individuals with RA. This very low-level evidence suggests that TNFi therapy can be safely administered in HCV-positive patients, if treatment with antiviral therapy is used. One small, long-term observational study of HCV-positive individuals receiving TNFi immunosuppression found that increased HCV activity was associated with the absence of concomitant antiviral therapy (93). In a small RCT of HCV-positive individuals with RA who did not require antiviral therapy, neither patients treated with MTX nor patients treated with TNFi therapy demonstrated significant change in viral load (98). The Voting Panel recommended that rheumatologists collaborate with gastroenterologists and/or hepatologists in recommending individualized treatment based on other comorbidities, reason(s) for not receiving HCV treatment, and the need to minimize immunosuppression, and consider using DMARDs other than MTX or leflunomide, such as sulfasalazine or hydroxychloroquine.

Malignancy

Previous melanoma and non-melanoma skin cancer. Separate PICO questions addressed melanoma and non-melanoma skin cancer, but the recommendations were similar, and therefore were combined.

PICOs F.1, F.2, F.3, and F.4. The recommendation is *conditional* because 1) the evidence is of very low quality, 2) due to potentially lower risk of recurrence of skin cancer with DMARDs versus other therapies based on clinical experience and 2 retrospective studies (104,105), and 3) a lack of data and knowledge about some of the mechanisms of action of biologics and tofacitinib, which may potentially contribute to an increased cancer risk. DMARDs were considered less immunosuppressive than biologics. The Voting Panel also stated that host factors may vary and may influence the risk of

High-risk condition	Recommendation	Level of Evidence (evidence reviewed)
Congestive heart failure¹		
CHF	Use combination DMARDs <u>or</u> non-TNF biologic <u>or</u> tofacitinib <u>over</u> TNFi (PICO C.1, C.2 and C.3).	Moderate to Very low (83,84)
CHF worsening on current TNFi therapy	Use combination DMARDs <u>or</u> non-TNF biologic <u>or</u> tofacitinib <u>over</u> another TNFi (PICO C.4, C.5 and C.6).	Very low ⁷
Hepatitis B²		
Active Hepatitis B infection and receiving/received effective antiviral treatment	Same recommendations as in patients without this condition (PICO D.1).	Very low (85-92)
Hepatitis C²		
Hepatitis C infection and receiving/received effective antiviral treatment	Same recommendations as in patients without this condition (PICO E.1).	Very low (92-103)
Hepatitis C infection and not receiving or requiring effective antiviral treatment	Use DMARDs <u>over</u> TNFi (PICO E.2) ³ .	Very low (92-103)
Past history of treated or untreated malignancy⁴		
Previously treated or untreated skin cancer (non-melanoma or melanoma)	Use DMARDs <u>over</u> biologics in melanoma (PICO F.1). Use DMARDs <u>over</u> tofacitinib in melanoma (PICO F.2). Use DMARDs <u>over</u> biologics in non-melanoma (PICO F.3). Use DMARDs <u>over</u> tofacitinib in non-melanoma (PICO F.4).	Very low (104-106)
Previously treated lymphoproliferative disorder	Use rituximab <u>over</u> TNFi (PICO G.1).	Very low (105,107)
Previously treated lymphoproliferative disorder	Use combination DMARD <u>or</u> abatacept <u>or</u> tocilizumab <u>over</u> TNFi (PICO G.2, G.3 and G.4).	Very low (105,107)
Previously treated solid organ malignancy	Same recommendations as in patients without this condition (PICO H.1).	Very low (105,108)
Previous Serious Infection(s)⁵		
Previous Serious infection(s)	Use combination DMARD <u>over</u> TNFi (PICO I.1) ⁵ . Use abatacept <u>over</u> TNFi (PICO I.2) ⁶ .	Very low (109-116)

Figure 7. Summary of 2015 American College of Rheumatology recommendations for high-risk patients with established rheumatoid arthritis with moderate or high disease activity and congestive heart failure (CHF), hepatitis B or C, past history of malignancy, or serious infection(s). Green and bolded = strong recommendation. A strong recommendation means that the panel was confident that the desirable effects of following the recommendation outweigh the undesirable effects (or vice versa), so the course of action would apply to most patients, and only a small proportion would not want to follow the recommendation. Yellow and italicized = conditional recommendation. The desirable effects of following the recommendation probably outweigh the undesirable effects, so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach. A treatment recommendation favoring one medication over another means that the preferred medication would be the recommended first option and the nonpreferred medication may be the second option. Favoring one medication over the other does not imply that the nonfavored medication is contraindicated for use; it is still an option. 1 = conditional recommendations supported by evidence level ranging from moderate level to no evidence, supported by clinical experience and the Food and Drug Administration safety warning with tumor necrosis factor inhibitors (TNFi). 2 = strong recommendations for Hepatitis B were largely based upon the recent American Association for the Study of Liver Diseases practice guidelines (85,86) and clinical experience; conditional recommendations for Hepatitis C were largely supported by very low level evidence based upon case series and clinical experience. 3 = consider using DMARDs other than methotrexate or leflunomide, such as sulfasalazine or hydroxychloroquine. 4 = conditional recommendations supported by level of evidence ranging from very low to no evidence, are largely based upon expert opinion and clinical experience. 5 = conditional recommendation was supported by very low level evidence. 6 = there was no consensus for making recommendations regarding the use of rituximab over TNFi or the use of tocilizumab over TNFi in this setting, due to indirect evidence (e.g., no comparison to TNFi or including patients with tuberculosis) and differences of opinion. In 1 study, compared to patients who restarted their previous TNFi following hospitalized infections, patients who switched to abatacept exhibited lower risk of subsequent hospitalized infections among the therapies examined. 7 = no studies were available, leading to very low quality evidence, and the recommendation was based on clinical experience. DMARDs = disease-modifying antirheumatic drugs; PICO = population, intervention, comparator, and outcomes.

	Killed vaccines			Recombinant vaccine	Live attenuated vaccine
	Pneumococcal ¹	Influenza (intramuscular)	Hepatitis B ²	Human Papilloma	Herpes Zoster ³
Before initiating therapy					
DMARD monotherapy	✓	✓	✓	✓	✓
Combination DMARDs	✓	✓	✓	✓	✓
TNFi biologics	✓	✓	✓	✓	✓ (PICO J.1) ⁵
Non-TNF biologics	✓	✓	✓	✓	✓ (PICO J.1) ⁵
While already taking therapy					
DMARD monotherapy	✓	✓	✓	✓	✓
Combination DMARDs	✓	✓	✓	✓	✓
TNFi biologics	✓	✓	✓ (PICO J.4, J.5) ⁶	✓	Not recommended (PICO J.2, J.3) ⁷
Non-TNF biologics ⁴	✓	✓	✓ (PICO J.4, J.5) ⁶	✓	Not recommended (PICO J.2, J.3) ⁷

Figure 8. 2015 American College of Rheumatology (ACR) recommendations update regarding the use of vaccines in patients with rheumatoid arthritis (RA) starting or currently receiving disease-modifying antirheumatic drugs (DMARDs) or biologics. ✓ = recommend vaccination when indicated (based on age and risk). Red indicates vaccinations not recommended. The panel endorsed all 2012 RA treatment recommendations for vaccination with 1 exception (see footnote 6), and re-voted only for certain immunization recommendations in patients receiving biologics. All recommendations were *conditional*, except that the panel strongly recommended (in green) using appropriately indicated killed/inactivated vaccines in patients with early or established RA who are currently receiving biologics. Evidence level was very low for recommendations based on population, intervention, comparator, and outcomes (PICOs) J.1, J.2, J.3, J.4, and J.5. Evidence level for the remaining recommendations that were endorsed from the 2012 ACR RA treatment guideline was similar (on a different scale). 1 = the Centers for Disease Control and Prevention (CDC) also recommends a one-time pneumococcal revaccination after 5 years for persons with chronic conditions such as RA. The CDC recommends pneumococcal conjugate vaccine (PCV13 or Prevnar 13) for all children younger than 5 years of age, all adults ≥65 years, and persons 6–64 years of age with certain medical conditions. Pneumovax is a 23-valent pneumococcal polysaccharide vaccine (PPSV23) that is currently recommended for use in all adults ≥65 years old and for persons who are ≥2 years old and at high risk for pneumococcal disease (e.g., those with sickle cell disease, HIV infection, or other immunocompromising conditions). PPSV23 is also recommended for use in adults 19–64 years of age who smoke cigarettes or who have asthma (http://www.cdc.gov/vaccines/vpd-vac/pneumo/default.htm?s_cid=cs_797). 2 = if hepatitis B risk factors are present (e.g., intravenous drug abuse, multiple sex partners in the previous 6 months, health care personnel). 3 = the panel conditionally recommended that in RA patients ages ≥50 years, the herpes zoster vaccine should be given before the patient receives biologic therapy or tofacitinib for their RA. 4 = response to certain killed vaccines may be reduced after rituximab therapy. 5 = the panel conditionally recommended giving the herpes zoster vaccine before the patient receives biologic therapy or tofacitinib for their RA in both early or established RA patients ages ≥50 years (PICO J.1). The panel also voted that after giving the herpes zoster vaccine, there should be a 2-week waiting period before starting biologics. 6 = the panel strongly recommended that in patients with early or established RA who are currently receiving biologics, appropriately indicated killed/inactivated vaccines should be used (PICOs J.4 and J.5). 7 = the panel conditionally recommended that in early or established RA patients who are currently receiving biologics, live attenuated vaccines such as the herpes zoster (shingles) vaccine should not be used (PICOs J.2 and J.3). TNFi = tumor necrosis factor inhibitor. For definitions and descriptions, see Table 1. Adapted from ref. 5.

recurrence of skin cancer. Even though biologics were not the first option, several Voting Panel members indicated that if the joint disease was moderately or highly active in the setting of a low-grade melanoma or non-melanoma skin cancer that had been previously treated, biologics would be an acceptable option with close skin surveillance in conjunction with a dermatologist.

It is important to note that although the panel voting on PICO F.3 (using a DMARD rather than a biologic for patients with a prior history of non-melanoma skin cancer) achieved the necessary 70% threshold for consensus, there was 1 Voting Panel member with a dissenting view that the risk difference between DMARDs and biologics in RA patients with a previously treated or untreated non-melanoma skin cancer may be insignificant, and 2 other Voting Panel members also shared some of these concerns but voted conditionally in favor of DMARDs.

Previous lymphoproliferative disorders

PICO G.1. The recommendation is **strong** despite very low quality evidence because rituximab is an approved treatment for some of these disorders and the best available clinical trial data suggest that there is a signal in clinical trials of induction and/or an increased risk of lymphoma in patients treated with TNFi (105,107).

PICOs G.2, G.3, and G.4. The recommendation is *conditional* because 1) the evidence is of very low quality (105,107), 2) there is a lack of evidence for combination DMARD therapy versus TNFi (PICO G.2), and 3) as described in PICO G.1, there is a possible increased risk of lymphoma associated with TNFi, but there is no evidence that abatacept or tocilizumab increases this risk (PICOs G.3 and G.4).

Previous solid organ cancer

PICO H.1. The recommendation is *conditional* because the evidence is of very low quality (105,108).

Serious infections

PICOs I.1 and I.2. The recommendation is *conditional* because 1) the evidence is of very low quality (indirect), as most trials excluded patient groups with a high risk of serious infections, and 2) rheumatologists have greater experience with DMARDs compared to TNFi in patients with previous serious infections. The recommendation regarding abatacept is conditional because the evidence is very low quality. In one study, compared to patients who restarted their previous TNFi following hospitalized infections, patients who switched to abatacept exhibited the lowest risk of subsequent hospitalized infection among the therapies examined (109).

Recommendations for use of vaccines in RA patients receiving DMARD and/or biologic therapy

Recommendations for use of vaccines in RA patients on DMARD and/or biologic therapy are provided in Figure 8.

PICO J.1. The recommendation is *conditional* because the evidence is of very low quality. The CDC has recommended the herpes zoster vaccine for people ages ≥ 60 years in the general population, but not for adults ages 50–59 years, even though the FDA approved the vaccine in adults ≥ 50 years. The CDC reconsidered the use of vaccination in people 50–59 years in 2013 and decided not to change its current recommendation for the general population, but did not vote (126). Our Voting Panel considered these recommendations and, because the immune systems of RA patients are compromised by the disease or by medications, the panel agreed that patients with RA ages ≥ 50 years should be vaccinated before receiving biologic or tofacitinib therapy because the benefits of doing so likely outweigh the risks in this population.

PICOs J.2 and J.3. The recommendation is *conditional* because 1) the evidence is of very low quality (127,128), and 2) there is a safety warning about the use of live vaccines in patients receiving biologics (127,128) (see Zostavax packet insert available at https://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf).

PICOs J.4 and J.5. The recommendation is **strong** despite very low quality of evidence (129–135) because of the documented benefit of killed vaccines in adults and no significant concerns of harm in RA patients receiving biologics, as per the general guidance from the CDC. Clinicians should consult the CDC recommendations for killed vaccines (136–140). Responses to some killed vaccines may

be reduced after rituximab therapy (141) and possibly after MTX therapy. Whenever possible, vaccines should be given *prior to* receiving therapy.

In addition to these recommendations, the Voting Panel endorsed the vaccination recommendations made in 2012, with the 1 exception mentioned above, i.e., responses to certain killed vaccines may be reduced after rituximab therapy (141) (Figure 8).

DISCUSSION

The 2015 ACR RA treatment guideline addresses the use of DMARDs, biologics, tofacitinib, and glucocorticoids in early and established RA and the use of various treatment approaches in frequently encountered clinical scenarios, including treat-to-target, switching between therapies, tapering of therapy, the use of biologics and DMARDs in high-risk RA patients, vaccination in patients with RA receiving DMARDs or biologics, TB screening with biologics or tofacitinib, and laboratory monitoring with DMARDs. The recommendations aim to provide guidance for clinicians and patients in an era of rapid advances in the treatment of RA. These recommendations were developed using scientific evidence, a rigorous, well-defined guideline development methodology, and a group consensus process. Compared to earlier treatment guidelines, there were several differences in the development of the 2015 RA treatment recommendations.

First, we used the GRADE methodology because it provides an internationally accepted systematic approach to guideline development. PICO questions were developed with the intended patient populations and outcomes explicitly listed. Before beginning the evidence synthesis, we posted the PICO questions online and solicited feedback and comments from the ACR membership. We also noted dissenting views. An example is the dissenting view related to the conditional recommendation for DMARDs over biologics for RA patients with previously treated or untreated non-melanoma skin cancer. Even though the panel reached consensus with 90% voting in favor, 1 panel member had a dissenting opinion and voted for biologic therapy over DMARD therapy in this situation. It should be noted that melanoma and non-melanoma were considered and voted on separately by the panel but that the final recommendations were similar for both situations and, therefore, are presented as a single recommendation.

Unlike previous ACR RA guidelines, the panel decided to base these new recommendations only on patients' disease activity level rather than including both disease activity and prognosis. The justification for this approach was that adding another variable (prognosis) to the PICO questions would have made the project much less feasible. Also, the Content Panel and the Voting Panel agreed that disease prognosis was largely captured in the concept of disease activity and that information regarding prognosis was unlikely to further contribute to decision-making.

Recommendations related to immunization and treatment in patients with RA and coexistent viral hepatitis B or C were informed primarily by the CDC (138) and the AASLD guidelines (85,86), respectively, and require fur-

ther explanation. The panel made a *conditional* recommendation to use herpes zoster immunization at age 50 and older prior to starting biologics, considering the higher infection risk due to RA and its treatments. This is consonant with the FDA approval for the use of herpes zoster vaccine in adults ages ≥ 50 years, and despite current CDC recommendations to use the vaccine in the general population (i.e., not RA patients) at ages ≥ 60 years. The panel also stated that as long as RA patients with viral hepatitis were started on the appropriate antiviral treatments for hepatitis B and C prior to initiation of RA therapy, they could be treated similarly to RA patients without these chronic viral infections. Case reports, case series, and small observational studies of RA patients with hepatitis B or C who have been treated with medications for RA provided additional supportive evidence. However, the data are limited in these clinical settings, and close monitoring of such patients and consultation with the appropriate specialists is advised.

The Voting Panel strongly recommended the use of combination traditional DMARDs *or* addition of a TNFi *or* a non-TNF biologic *or* tofacitinib for patients with established RA with moderate or high disease activity despite DMARD monotherapy. After carefully considering the evidence, the panel concluded that the limited direct comparative evidence for these therapies in this clinical situation precluded recommending a ranking of these treatment options.

Due to rapidly evolving knowledge for the treatment of RA, some recommendations may be outdated by the time they are published due to the emergence of new evidence. Examples include new data on tapering and discontinuation of therapies in early RA (142) and treat-to-target (143). The short half-life of treatment recommendations is also related to the rigorous and time-consuming process of guideline development used by the ACR, which complies with guidance from the National Academy of Medicine (formerly the Institute of Medicine) and the Council for Medical Specialty Societies. Additional time is also required for review and endorsement of each guideline document by ACR committees, journal reviewers and editors, and the ACR Board of Directors. However, the ACR regularly updates RA guidelines and strives to shorten the time between the end of the literature review and the publication of guidelines, to make them as relevant and current as possible.

The panel provided “conditions” when making a conditional recommendation. The listed conditions were not necessarily exhaustive for each recommendation, but included those factors that were most important in determining the final panel vote. This process ensured that conditions were a direct reflection of the Voting Panel members’ discussion and agreements. Although we used 70% as the agreement threshold, for 80% of the recommendations there was 90% consensus (of which 50% of the recommendations had 100% consensus). We noted that 77% of the recommendations were conditional and the remaining 23% were strong. This was partially due to the lack of evidence for common clinical situations, and our a priori decision that PICO questions should be based on what is important for a clinician and patient to know, not based on the presence or absence of the highest level of evidence. This indicates that more evi-

dence is needed to derive strong RA recommendations in the future. A number of recommendations were strong despite low quality evidence, which is allowed according to GRADE methodology, and the Voting Panel provided justification for these recommendations.

Several important aspects of RA care were not addressed due to resource limitations, including the use of nonpharmacologic interventions (e.g., physical therapy, occupational therapy, assistive devices), use of biologics and DMARDs in other less-common conditions (e.g., new diagnosis of cancer, family history of cancer or multiple sclerosis, new diagnosis of hepatitis while receiving successful RA therapy). The Voting Panel considered the dosing issues related to glucocorticoids and MTX and believed strongly that it was not within its charge to mandate dosing. Recommendations for individual medications (e.g., various DMARDs, TNFi, non-TNF biologics) were not made, since an a priori decision was made to examine these as categories for feasibility reasons. Although we recognize that other disease activity measures have become available since the ACR endorsed 6 measures in its 2012 paper (16), it was outside the scope of this guideline effort to reevaluate measures and recommend to the ACR an updated list for possible endorsement.

A targeted literature search was performed for biosimilars, but there was too little evidence for the panel to provide recommendations on this complex issue at present. In addition, at the time of panel voting, biosimilars for RA were not yet approved for use in the US. The ACR has published a position statement on biosimilars (available at <http://www.rheumatology.org/Practice-Quality/Administrative-Support/Position-Statements>) that may provide some guidance for interested readers. The team recommended that biosimilars in RA therapy should be considered for future research agendas and RA guideline efforts.

The team also discussed the following topics and recommended that they be targeted for future research: use of biologics and DMARDs during the period of conception, pregnancy, and breastfeeding; treatment of RA with interstitial lung disease; laboratory monitoring for biologics/tofacitinib; and biomarker testing.

The 2015 ACR RA treatment recommendations apply to common clinical situations, since the panel considered issues common to most patients, not exceptions. In an effort to standardize terminology, the ACR has asked that the term “guideline” be used when referring to a guideline paper and the term “recommendation” when referring to an individual recommendation statement within the guideline paper. The use of the term “guideline” should not be construed as a mandate that every clinician/patient should follow the recommendations made in every clinical situation. These recommendations are not proscriptive and should be used by clinicians and patients as a guide for discussion related to RA treatments. Only a clinician’s assessment, an active patient-physician dialogue, and collaborative decision-making will result in the optimal risk/benefit analysis. The best treatment decisions will be made by clinicians incorporating patients’ values and preferences. Thus, the choice of the best treatment in some cases may be other options in the algorithm/recommendation rather than the first option in the treatment recommendation algorithm.

These recommendations are not intended to support payment or insurance decisions and should not be used for denial of treatments to patients. These recommendations cannot adequately convey all uncertainties and nuances of patient care in the real world. For example, a listing of all conditions entertained in each conditional recommendation is not feasible. We also noted that for newer drugs (e.g., tofacitinib), long-term experience and safety data are usually lacking, and additional data are needed to increase the confidence of clinicians in utilizing such medications.

In conclusion, the 2015 ACR RA pharmacologic treatment guideline is comprehensive and provides guidance to clinicians and patients regarding the treatment of RA. Using state-of-the-art methodology (GRADE) and a well-defined group-consensus technique, our guideline development process was systematic, explicit, and transparent. Periodic updates of this guideline, as required by the ACR for all of its guidelines, will ensure that this RA treatment guideline remains current and usable for patients and physicians for treatment decision-making in RA. Finally, the 2015 ACR RA treatment guideline is a useful tool not only to guide treatment in clinical practice but also to facilitate discussion about individualized treatment decision-making between patients and their clinicians.

ACKNOWLEDGMENTS

We thank Ms Regina Parker (ACR staff) for assistance in organizing the face-to-face meeting and coordinating the administrative aspects of the project, Ms Janet Joyce for help in developing the literature search strategy and performing the literature search and updates, and Ms Tamara Radar for peer reviewing the literature search strategy. We thank William Sanchez, MD (Consultant, Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN) for providing expert advice regarding treatment of RA in the presence of hepatitis B or C.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Singh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Singh, Saag, Bridges, Akl, Bannuru, Sullivan, Vaysbrot, McNaughton, Osani, Shmerling, Curtis, Furst, Parks, Kavanaugh, O'Dell, King, Leong, Matteson, Schousboe, Drevlow, Ginsberg, Grober, St.Clair, Tindall, Miller, McAlindon.

Acquisition of data. Singh, Saag, Bridges, Akl, Bannuru, Sullivan, Vaysbrot, McNaughton, Osani, Shmerling, Curtis, Furst, Parks, Kavanaugh, O'Dell, King, Leong, Matteson, Schousboe, Drevlow, Ginsberg, Grober, St.Clair, Tindall, Miller, McAlindon.

Analysis and interpretation of data. Singh, Saag, Bridges, Akl, Bannuru, Sullivan, Vaysbrot, McNaughton, Osani, Shmerling, Curtis, Furst, Parks, Kavanaugh, O'Dell, King, Leong, Matteson, Schousboe, Drevlow, Ginsberg, Grober, St.Clair, Tindall, Miller, McAlindon.

REFERENCES

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. *Arthritis Rheum* 2008;58:15–25.
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum* 1984;27:864–72.
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. *Circulation* 2003;107:1303–7.
4. Salaffi F, Sarzi-Puttini P, Girolimetti R, Atzeni F, Gasparini S, Grassi W. Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. *Clin Exp Rheumatol* 2009;27(5 Suppl 56):S67–74.
5. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2012;64: 625–39.
6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Rheum* 2008;59:762–84.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
8. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol* 2013;66:719–25.
9. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation: determinants of a recommendation's direction and strength. *J Clin Epidemiol* 2013;66:726–35.
10. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64:395–400.
11. Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for studies. Higgins JP, Green S, editors. *Cochrane handbook for systematic reviews of interventions*, version 5.1.0. London: The Cochrane Collaboration; 2011. URL: www.cochrane-handbook.org.
12. Review Manager (RevMan) [computer program], version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
13. Schunemann H, Tugwell P, Reeves BC, Akl EA, Santesso N, Spencer FA, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. *Res Synth Methods* 2013;4:49–62.
14. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. *J Clin Epidemiol* 2013;66:151–7.
15. Jaeschke R, Guyatt GH, Dellinger P, Schunemann H, Levy MM, Kunz R, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. *BMJ* 2008;337:a744.
16. Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care Res (Hoboken)* 2012;64:640–7.
17. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission.

- Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007;66:1443–9.
18. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. *Ann Rheum Dis* 2007;66:235–41.
 19. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2002;137:726–33.
 20. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis* 1999;58:220–5.
 21. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. *Br J Rheumatol* 1997;36:1082–8.
 22. De Jong PH, Hazes JM, Barendregt PJ, Huisman M, van Zeben D, van der Lubbe PA, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. *Ann Rheum Dis* 2013;72:72–8.
 23. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the Treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum* 2012;64:2824–35.
 24. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. *Arthritis Rheum* 2008;58:1310–7.
 25. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. and the FIN-RACo Trial Group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. *Lancet* 1999;353:1568–73.
 26. Van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. *Lancet* 2012;379:1712–20.
 27. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. *J Rheumatol* 2011;38:2169–71.
 28. Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIB, multinational, prospective, randomized study. *Arthritis Rheum* 2013;65:28–38.
 29. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum* 2012;64:617–29.
 30. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med* 2012;367:508–19.
 31. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2012;156:329–39.
 32. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R. Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. *Arthritis Res Ther* 2012;14:R112.
 33. Todoerti M, Scire CA, Boffini N, Bugatti S, Montecucco C, Caporali R. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. *Ann N Y Acad Sci* 2010;1193:139–45.
 34. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. *Ann Rheum Dis* 2008;67:656–63.
 35. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. *Arthritis Rheum* 2005;52:3360–70.
 36. Wassenberg S, Rau R, Steinfeld P, Zeidler H, for the Low-Dose Prednisolone Therapy Study Group. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2005;52:3371–80.
 37. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low-dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. *Ann Rheum Dis* 2004;63:797–803.
 38. Van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. *Ann Intern Med* 2002;136:1–12.
 39. Kirwan JR, Hallgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. *Ann Rheum Dis* 2004;63:688–95.
 40. Durez P, Malgheem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis Rheum* 2007;56:3919–27.
 41. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. *Ann Rheum Dis* 2005;64:1288–93.
 42. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. *Arthritis Rheum* 2004;50:3783–91.
 43. Ciconelli RM, Ferraz MB, Visionsi RA, Oliveira LM, Atra E. A randomized double-blind controlled trial of sulphasalazine combined with pulses of methylprednisolone or placebo in the treatment of rheumatoid arthritis. *Br J Rheumatol* 1996;35:150–4.
 44. Fransen J, Moens HB, Speyer I, van Riel PL. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. *Ann Rheum Dis* 2005;64:1294–8.
 45. Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. *Health Technol Assess* 2005;9:1–78.
 46. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight con-

- trol for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. *Lancet* 2004;364:263–9.
47. Ostergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, et al. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naïve rheumatoid arthritis patients. *Arthritis Rheum* 2011;63:3712–22.
 48. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum* 2009;60:2272–83.
 49. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. *N Engl J Med* 2014;370:2377–86.
 50. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013;381:1541–50.
 51. Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis* 2014;73:86–94.
 52. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis* 2008;67:1096–103.
 53. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. *Lancet* 2013;381:451–60.
 54. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with non-biologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2013;159:253–61.
 55. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum* 2013;65:559–70.
 56. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med* 2012;367:495–507.
 57. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. *Arthritis Rheum* 2012;64:970–81.
 58. Tanaka Y, Suzuki M, Nakamura H, Toyozumi S, Zwillich SH, and the Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Arthritis Care Res (Hoboken)* 2011;63:1150–8.
 59. O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. *N Engl J Med* 2013;369:307–18.
 60. Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. *Mod Rheumatol* 2010;20:531–8.
 61. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2010;62:917–28.
 62. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis* 2009;68:789–96.
 63. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. *Ann Rheum Dis* 2006;65:1357–62.
 64. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;363:675–81.
 65. Van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. *Ann Rheum Dis* 2006;65:1478–83.
 66. Chatzidionysiou K, van Vollenhoven RF. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. *Scand J Rheumatol* 2013;42:190–5.
 67. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNF α blocker failure. *Biologics* 2012;6:191–9.
 68. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM, on behalf of the British Society for Rheumatology Biologics Register. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. *Arthritis Care Res (Hoboken)* 2012;64:1108–15.
 69. Emery P, Gottenberg JE, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada VM, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. *Ann Rheum Dis* 2015;74:979–84.
 70. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, et al. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. *Ann Rheum Dis* 2015;74:430–6.
 71. Wakabayashi H, Hasegawa M, Nishioka Y, Sudo A, Nishioka K. Which subgroup of rheumatoid arthritis patients benefits from switching to tocilizumab versus etanercept after previous infliximab failure? A retrospective study. *Mod Rheumatol* 2012;22:116–21.
 72. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. on behalf of the physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. *Arthritis Rheum* 2007;56:1417–23.
 73. Johnston SS, Turpcu A, Shi N, Fowler R, Chu BC, Alexander K. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent: a retrospective administrative claims analysis. *Semin Arthritis Rheum* 2013;43:39–47.
 74. Gomez-Reino JJ, Maneiro JR, Ruiz J, Rosello R, Sanmarti R, Romero AB. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus

- switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. *Ann Rheum Dis* 2012;71:1861–4.
75. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? *Ann Rheum Dis* 2010;69:387–93.
 76. Buttgerit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). *Ann Rheum Dis* 2013;72:204–10.
 77. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. *Ann Rheum Dis* 1999;58:713–8.
 78. Ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. *Lancet* 1996;347:347–52.
 79. Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, et al. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. *Lancet* 2014;383:321–32.
 80. Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. *Lancet* 2013;381:918–29.
 81. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315–24.
 82. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010;62:2569–81.
 83. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004;109:1594–602.
 84. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor α , in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107:3133–40.
 85. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007;45:507–39.
 86. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009;50:661–2.
 87. Thong BY, Koh ET, Chng HH, Chow WC. Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases. *Ann Acad Med Singapore* 2007;36:100–5.
 88. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor α therapy. *Ann Rheum Dis* 2011;70:1719–25.
 89. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. *Arthritis Care Res (Hoboken)* 2012;64:1265–8.
 90. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. *J Gastroenterol* 2011;46:556–64.
 91. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF- α therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology (Oxford)* 2006;45:1294–7.
 92. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor- α (TNF- α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. *Clin Rheumatol* 2009;28:787–91.
 93. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor- α inhibitors and chronic hepatitis C: a comprehensive literature review. *World J Gastroenterol* 2013;19:7867–73.
 94. Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. *Dig Dis Sci* 2013;58:1149–56.
 95. Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. *Rheumatology (Oxford)* 2007;46:97–9.
 96. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. *J Hepatol* 2005;42:315–22.
 97. Terrier B, Saadoun D, Sene D, Sellam J, Perard L, Coppere B, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. *Arthritis Rheum* 2009;60:2531–40.
 98. Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. *J Rheumatol* 2014;41:286–92.
 99. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor- α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. *J Rheumatol* 2008;35:1944–9.
 100. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. *Ann Rheum Dis* 2003;62:1078–82.
 101. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. *Arthritis Rheum* 2004;51:800–4.
 102. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. *Autoimmun Rev* 2008;8:104–6.
 103. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease-modifying antirheumatic drugs without antiviral prophylaxis. *J Rheumatol* 2008;35:421–4.
 104. Raaschou P, Simard JF, Holmqvist M, Asklund J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population-based prospective cohort study from Sweden. *BMJ* 2013;346:f1939.
 105. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP, on behalf of the British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. *Arthritis Care Res (Hoboken)* 2010;62:755–63.
 106. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. *J Rheumatol* 2005;32:2130–5.
 107. Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. *Arthritis Care Res (Hoboken)* 2014;66:1302–9.
 108. Raaschou P, Frisell T, Asklund J, for the ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. *Ann Rheum Dis* 2014. E-pub ahead of print.

109. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. *Ann Rheum Dis* 2015;74:1065–71.
110. Toussirot E, Pertuiset E, Sordet C, Auge B, Wendling D, Pallot-Prades B, et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. *Joint Bone Spine* 2010;77:142–5.
111. Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF- α antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. *Open Rheumatol J* 2012;6:286–9.
112. Denis B, Lefort A, Flipo RM, Tubach F, Lemann M, Ravaud P, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)- α antagonist therapy: safe re-initiation of TNF- α blockers after appropriate anti-tuberculous treatment. *Eur J Clin Microbiol Infect Dis* 2008;14:183–6.
113. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. *J Rheumatol* 2009;36:914–7.
114. Jo KW, Hong Y, Jung YJ, Yoo B, Lee CK, Kim YG, et al. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis. *Respir Med* 2013;107:1797–802.
115. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. *Ann Rheum Dis* 2008;67:710–2.
116. Nobre CA, Callado MR, Lima JR, Gomes KW, Martiniano GV, Vieira WP. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. *Rheumatol Int* 2012;32:2769–75.
117. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. *Hepatology* 2006;43:209–20.
118. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. *Gastroenterology* 1991;100:182–8.
119. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. *J Clin Oncol* 2013;31:2765–72.
120. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. *Ann Oncol* 2011;22:1170–80.
121. Hsu C, Hsiung CA, Su JJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. *Hepatology* 2008;47:844–53.
122. Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. *Hepatology* 2006;43:233–40.
123. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. *Gastroenterology* 2003;125:1742–9.
124. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. *Medicine (Baltimore)* 2011;90:359–71.
125. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. *Nat Rev Gastroenterol Hepatol* 2014;11:209–19.
126. Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR, and the Centers for Disease Control and Prevention. Update on recommendations for use of herpes zoster vaccine. *MMWR Morb Mortal Wkly Rep* 2014;63:729–31.
127. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. *JAMA* 2012;308:43–9.
128. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. *Arthritis Res Ther* 2011;13:R174.
129. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. *J Rheumatol* 2007;34:272–9.
130. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol* 2007;34:952–7.
131. Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. *J Rheumatol* 2004;31:1356–61.
132. Coulson E, Saravanan V, Hamilton J, So KL, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis* 2011;70:1289–91.
133. Kapetanovic MC, Roseman C, Jonsson G, Truedsson L, Saxne T, Geborek P. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. *Arthritis Rheum* 2011;63:3723–32.
134. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45:106–11.
135. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum* 2004;33:283–8.
136. Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older: United States, 2015. *Ann Intern Med* 2015;162:214–23.
137. Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older, United States, 2015. *MMWR Morb Mortal Wkly Rep* 2015;64:91–2.
138. US Department of Health and Human Services. Centers for Disease Control and Prevention. Recommended adult immunization schedule, United States 2014. URL: <http://www.cdc.gov/vaccines/schedules/downloads/adult/adult-schedule.pdf>.
139. National Center for Immunization and Respiratory Diseases. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60:1–64.
140. Advisory Committee on Immunization Practices. ACIP Recommendations: 2014. Immunization Action Coalition. URL: http://www.immunize.org/acip/acip_2014.asp.
141. Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum* 2010;62:64–74.
142. Emery P, Hammoudeh M, FitzGerald O, Combe B, Martin-Mola E, Buch MH, et al. Sustained remission with etanercept tapering in early rheumatoid arthritis. *N Engl J Med* 2014;371:1781–92.

143. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis* 2015. E-pub ahead of print.
144. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. *Rheum Dis Clin N Am* 2006;32:9–44.
145. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. *Arthritis Rheum* 2005;52:2625–36.
146. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727–35.
147. Pincus T. The American College of Rheumatology (ACR) Core Data Set and derivative “patient only” indices to assess rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23(5 Suppl 39):S109–13.
148. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. *J Rheumatol* 2005;32:2016–24.
149. Wolfe F, Michaud K, Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). *J Rheumatol* 2005;32:2410–5.
150. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. *Arthritis Rheum* 2005;52:3873–9.
151. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Arthritis Rheum* 2011;63:573–86.
152. Hurst JW, Morris DC, Alexander RW. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. *Clin Cardiol* 1999;22:385–90.
153. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet* 1997;350:309–18.
154. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. *BMJ* 2008;336:49–51.
155. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10–20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. *Best Pract Res Clin Rheumatol* 2007;21:755–87.
156. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther* 2005;7:R796–806.
157. Fransen J, Stucki G, van Riel P. Rheumatoid arthritis measures: Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). *Arthritis Rheum* 2003;49 Suppl:S214–24.
158. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology (Oxford)* 2003;42:244–57.
159. Centers for Disease Control and Prevention. Targeted tuberculosis testing and treatment of latent tuberculosis infection. *MMWR Mortal Morb Wkly Rep* 2000;49:1–51.
160. Centers for Disease Control and Prevention. Chapter 3. Testing for tuberculosis infection and disease. URL: <http://www.cdc.gov/tb/education/corecurr/pdf/chapter3.pdf>.

APPENDIX A: PANEL AND TEAM MEMBERS

Voting Panel: Arthur Kavanaugh, MD, James O'Dell, MD, Charles King, MD, Amye Leong, MBA, Eric L. Matteson, MD, MPH, John T. Schousboe, MD, PhD, Barbara Drevlow, MD, Seth Ginsberg, BSc, James Grober, MD, E. William St.Clair, MD, Elizabeth Tindall, MD.

Core Leadership Team: Jasvinder A. Singh, MBBS, MPH (Project Principal Investigator), Kenneth G. Saag, MD, MSc, S. Louis Bridges Jr., MD, PhD, Elie A. Akl, MD, MPH, PhD, Timothy McAlindon, MD, MPH.

Literature Review Team: Timothy McAlindon, MD, MPH (Literature Review Team Principal Investigator), Raveendhara R. Bannuru, MD, PhD, Matthew C. Sullivan, BA, Elizaveta Vaysbrot, MD, MS, Christine McNaughton, BS, Mikala Osani, BA, Janet Joyce, MLS, (Librarian, Ottawa, Ontario, Canada).

Content Panel: Robert H. Shmerling, MD, Jeffrey R. Curtis, MD, MS, MPH, Daniel E. Furst, MD, Deborah Parks, MD.